On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in [...]
A popular way to talk about the incredible progress that has been made in lung cancer treatments over the past few years is to share the statistic that more lung cancer treatments have been approved in the past three [...]
On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of [...]
On May 26, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab), Yervoy (ipilimumab), and two cycles of platinum-doublet chemotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having [...]
On May 8, 2020, the Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in RET under the accelerated approval pathway. The FDA based their approval on the [...]
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]